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Abstract: Pregnane X receptor (PXR, NR1I2) is a member of the ligand-activated nuclear receptor
superfamily. This receptor is promiscuous in its activation profile and is responsive to a broad array
of both endobiotic and xenobiotic ligands. PXR is involved in pivotal cellular detoxification processes
to include the regulation of genes that encode key drug-metabolizing cytochrome-P450 enzymes,
oxidative stress response, as well as enzymes that drive steroid and bile acid metabolism. While PXR
clearly has important regulatory roles in the liver and gastrointestinal tract, this nuclear receptor
also has biological functions in breast tissue. In this review, we highlight current knowledge of
PXR’s role in mammary tumor carcinogenesis. The elevated level of PXR expression in cancerous
breast tissue suggests a likely interface between aberrant cell division and xeno-protection in cancer
cells. Moreover, PXR itself exerts positive effect on the cell cycle, thereby predisposing tumor cells
to unchecked proliferation. Activation of PXR also plays a key role in regulating apoptosis, as well
as in acquired resistance to chemotherapeutic agents. The repressive role of PXR in regulating
inflammatory mediators along with the existence of genetic polymorphisms within the sequence of
the PXR gene may predispose individuals to developing breast cancer. Further investigations into the
role that PXR plays in driving tumorigenesis are needed.
Keywords: nuclear receptor; pregnane X receptor; xenobiotics; tumorigenesis; breast cancer

1. Introduction
Pregnane receptor (PXR) (NR1I2), termed steroid and xenobiotic receptor (SXR) in humans, is a
nuclear receptor that acts as a xenobiotic and endobiotic sensor that recognizes a large variety of
hydrophobic ligands [1]. PXR is highly expressed in small intestine, liver, rectum, colon, and gallbladder,
but is also expressed in comparatively lower levels in reproductive tissues including breast tissue [2,3].
First discovered in 1998, PXR is a key regulator of the expression of cytochrome-P 450 (CYP) enzymes,
including CYP3A4 and CYP2B6 [4–8], which metabolize a variety of toxins, carcinogens, and clinically
relevant chemotherapeutic agents (i.e., tamoxifen and doxorubicin) [1,9–13]. The role of PXR as a
nuclear receptor has evolved to also include regulation of families of genes involved in oxidative
stress, steroid and bile acid metabolism, inflammation, apoptosis, cell proliferation, and cell cycle
maintenance [14–18]. Activation of PXR regulates key aspects of cancer cell biology to include tumor
metastasis, angiogenesis, acquisition of chemotherapeutic resistance, and the inflammatory immune
response [1,2,19].
PXR activity is governed by the coordinated efforts of ligands, other nuclear receptors and cofactors,
as well as epigenetic and post-translational modifications such as phosphorylation, acetylation,
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ubiquitination, and SUMOlytion. The DNA-binding activity of PXR is activated by a wide variety
of endobiotic compounds including steroid hormones and bile acids such as estrogen or lithocholic
acid, respectively. PXR is also activated by a plethora of exogenous compounds including xenobiotic
chemicals, food ingredients, and a wide variety of herbal remedies and pharmaceutical agents. The net
effect of canonical ligand-mediated PXR activation in mammals is the coordinate regulation of a
pathway of genes that encode pivotal hepatic and intestinal proteins which are involved in the
coordinate uptake, biotransformation, and eventual excretion of a myriad of specific—and potentially
toxic—metabolites in feces or urine [1].
The activation of PXR regulates the expression of hepatic uptake drug and bile acid transporter
proteins including organic anion transporting polypeptide protein 2 (Oatp2) and organic cation
transporter 1 (Oct1) [20–22]. Multi-drug resistance-associated protein 2 (MRP2) and MRP3, both of
which are responsible for efflux on conjugated substrates into bile or blood, respectively, are proteins
encoded by PXR-target genes [22–24]. In the intestine, another PXR-target gene is multi-drug resistance
1 (MDR1) that encodes P-glycoprotein 1 (P-gp) [25,26], another broad selective drug efflux membrane
transporter. Because PXR is important for the uptake and efflux of steroid hormones and metabolites
due to the variety of transport proteins that are encoded by PXR-target genes, its ability to link
endocrinology, pharmacology, and cancer biology is essential to maintaining cellular homeostasis.
Given the breadth of compounds that activate PXR and its role in the coordination between
multiple biological processes, it makes sense that there would be crosstalk between PXR and other
nuclear receptors including farnesoid X receptor (FXR), constitutive androstane receptor (CAR),
peroxisome proliferator-activated receptor alpha (PPARα), liver X receptor (LXR) and androgen
receptor [2]. In addition, like other nuclear receptors, PXR activity is modulated by a number of
cofactors further placing PXR as a nexus of molecular signaling. The PXR corepressors, nuclear receptor
corepressor 1 (NCoR1) and NCoR2 (also known as silencing mediator of retinoid and thyroid hormone
receptors, SMRT), are bound to inactive PXR until an activator is present. Additional PXR corepressors
include sterol regulatory element binding protein 1 (SREBP-1) and forkhead box A 2 transcription factor
(FOXA2) [2,27,28]. Activators of PXR, which include some anticancer drugs, induce a conformational
change resulting in dissociation of corepressors and recruitment of coactivators [19]. Coactivators that
have been identified include steroid receptor coactivators (SRCs) 1, 2 and 3, peroxisome proliferator
activated receptor gamma coactivator 1-alpha (PGC-1α), forkhead box O 1 transcription factor (FOXO1),
protein arginine methyltransferase (PRMT) and p300 [2,29,30]. Thus, activity of PXR can be influenced
by a number of factors including and excluding direct activators or inhibitors. In this review, we will
summarize the current knowledge of the mechanisms of PXR’s role in breast cancer. PXR is an
intriguing molecule in cancer because it has been observed to play a role in apoptosis, oxidative
stress, cell cycle arrest, tissue growth, proliferation, and tumor aggressiveness, as well as serving
as a marker of poor prognosis in cancer patients [14,15,31–34]. PXR also is involved in metabolism
of estrogen and estrogen metabolites, in addition to chemotherapeutic drugs making it a potential
therapeutic target.
2. PXR and Breast Cancer
2.1. PXR and the Cell Cycle
The primarily anti-apoptotic role of PXR in the cell cycle and cell proliferation has been evidenced
through research on hepatocytes. It has long been established that PXR activation in hepatocytes
can induce liver regeneration and even lead to hepatomegaly. PXR was specifically found to do this
through an interaction with YAP [35]. Shizu et al. (2013) also demonstrated this in a study which
showed that PXR stimulation with PCN induced proliferation in liver cells. PXR has also been found
to induce proliferation of human breast cancer cells [31,36–39]. It was further shown that the treated
breast cancer cells had decreased levels of p27 and p130 mRNA, both of which inhibit entry of quiescent
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cells into the cell cycle [40]. Overall, these studies point toward PXR causing increased cell cycle
progression in hepatocytes and potentially human breast cancer.
The relationship of p53 and PXR is likely also important in PXRs role in cancer. The tumor
suppressor p53 is essential for inducing cell cycle arrest in DNA damaged cells and is often referred to
as the ‘guardian of the genome’. Without activated p53, the cell cycle goes unchecked predisposing it
to malignancy. Recent studies have demonstrated that PXR exerts an inhibitory effect on p53 through
reducing p53 transactivation along with the expression of target genes involved in apoptosis and cell
cycle arrest [41]. Alternately, activated p53 suppresses PXR and therefore drug metabolism, which can
enhance chemotherapeutic effects [42].
Another study provided further evidence for the antiapoptotic function of PXR independent of its
drug detoxifying effects through the upregulation of antiapoptotic proteins and downregulation of
proapoptotic proteins. In the study, PXR-producing colon cancer cells were exposed to deoxycholic
acid, a component of bile acid capable of inducing apoptosis in colon epithelium, both in the presence
and absence of a PXR agonist. Expression of antiapoptotic genes—BAG3, BIRC2, and MCL-1—were
subsequently found to be elevated while proapoptotic genes BAK1 and p53 were decreased. Similar
results were observed in normal mice colon epithelium with activation of PXR leading to decreased
deoxycholic acid-induced apoptosis and increased sensitization to colon cancer [15]. While PXR
has been linked to some anti-apoptotic mechanisms in breast cancer, studies have indicated that
PXR induces apoptosis in the p53 wild-type breast cancer MCF-7 and ZR-75-1 cell lines following
upregulated expression of p21, PUMA, and BAX [43]. PXR knockdown using targeted siRNA was able
to block the PXR-induced apoptosis in MCF-7 cells, indicating a regulatory role of apoptosis induction
in breast cancer cells [43].
2.2. PXR and Chemotherapeutic Resistance
Acquired resistance to chemotherapies in tumor cells is a complex process, with multiple genes
likely involved. Changes in gene expression of multidrug resistant-associated proteins is thought to
play a major role in the transition from responsive to resistant cancers. Several downstream target
genes of PXR may be involved in this transition, including phase I metabolic enzymes, CYP enzymes,
phase II metabolic enzymes, glucuronyltransferase (UGT) and phase III drug transporters, multidrug
resistance protein 1 (MRP1), and breast cancer resistance protein (BCRP) [44,45].
Although PXR is expressed mainly in the liver, intestine, and colon tissues, it has been found to
be expressed in normal breast tissue, and at even higher levels in breast cancer tissue [31,36–39,43].
In addition, PXR expression has been shown to be induced in breast cancer cell lines MDA-MB-231
and MCF-7 in response to PXR ligand administration [46,47]. Forced overexpression of PXR in these
cells resulted in an increased promoter activity and cellular level of drug resistance proteins such as
MRP1 and BCRP [48,49]. MDR1 and BCRP are members of the ATP binding cassette (ABC) superfamily
of transporters, and function to increase the cellular outflow of many types of chemotherapeutic
drugs [50]. When overexpressed, or treated with the PXR agonist, SR12813, PXR reduced the response
in breast cancer cells to tamoxifen, cisplatin, and paclitaxel treatment, whereas its downregulation
restored cell cycle regulation and apoptosis [47,48]. Li et al., in 2016, provided evidence that the
protein arginine methyltransferase 1 (PMRT1), a known epigenetic modifier of histone H4, is an
important co-activator of PXR and aids in driving the expression of the MDR1 gene during acquired
chemoresistance [46]. In addition, significant correlations between BCRP expression and resistance to
5-FU treatment has been noted [51], as well as indications that PXR may modulate a TGF-β induced
resistance to chemotherapy in liver cells, via alterations to procaspase-3 and Mcl-1 levels [52].
The drug uptake transporter organic anion transporter polypeptide 1A2 (OATP1A2), which
mediates cellular uptake of estrogen metabolites, has also been documented as a downstream target of
PXR. OATP1A2 was first identified through its characterization of enhanced expression in breast cancer
as compared to healthy breast tissues [39]. Meyer zu Schwabedissen and colleagues (2008) demonstrated,
in T47-D cells, the activation of PXR through agonist treatment induces OATP1A2 expression in a time-
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and dose-dependent manner, resulting in enhanced estrogen receptor activation [38]. The authors
identified and confirmed a PXR response element in the human OATP1A2 promoter 5.8 kilo bases
upstream of the transcription initiation site. This provided insight into the interactions of PXR and its
downstream target, which may contribute to breast cancer pathogenesis and development of resistance
towards chemotherapy in breast cancers expressing PXR.
2.3. PXR and Metastasis and Angiogenesis
Cancer cell motility leading to metastasis, along with angiogenesis, are major components of
cancer progression and areas in which PXR may be involved. PXR, when activated, has been shown to
be sufficient at enhancing neoplastic characteristics including: cell growth, invasion, and metastasis
through activation of Fibroblast Growth Factor 19 (FGF19) gene expression in colon cancer. Shown
in both human colon tumor cell lines and in primary human colon cancer tissue xenografted into
immunodeficient mice, the role of PXR activation through FGF19 induction mediates colon cancer cell
proliferation and migration [14]. PXR’s implication for playing a role in human cancer metastasis may
also stem from it being shown to regulate morphology and cell motility via the signaling axes of PXR
GADD45β-p38MAPK and PXR-HNF4A-insulin-like growth factor-binding protein 1 (IGFBP1) [53,54].
Using hepatocellular carcinoma cells (HepG2) to investigate cell motility, it has been shown that
PXR activation leads to increased phosphorylation of p38 MAPK through GADD45β gene induction.
It was then observed that the HepG2 cells underwent epithelial-to-mesenchymal morphologic changes
leading to reorganization of actin filaments and increased cell migration [53]. This PXR-dependent
regulation of GADD45β and IGFBP1 helps support its diverse role in cellular regulation since both
genes are found in cellular processes including: apoptosis, the cell cycle, DNA repair, cell proliferation,
and cell migration [55]. These results can be correlated to a similar study on breast tissue done in 2002
by Bakin et al., who demonstrated that the p38 MAPK phosphorylation pathway is necessary for TGFβ
to induce cell migration in both tumor and non-tumor mammary epithelial cells [56]. This points to a
possibility that PXR can have similar cell migration-inducing effects in breast tissue as those observed
in HepG2 cells, although further research is necessary. Conversely, in a recent study on the effects of a
microbiome metabolite, indolepropionic acid (IPA), on PXR activation, Sari et al. (2020) showed that
patients with higher expression of PXR have increased survival rates in estrogen receptor-positive
cancers [57]. Furthermore, IPA supplementation in mice challenged with 4T1 breast cancer cells
showed reduced localized infiltration and metastases [57]. This suggests that PXR may target genes
and pathways that reduce breast cancer progression.
Another important factor that contributes to cancer growth and spread is angiogenesis. This process
is primarily mediated by vascular endothelial growth factor (VEGF) and nitric oxide (NO). This process
works first by the release of VEGF, which then activates the Nuclear Factor Kappa B (NF-κB) pathway
leading to an increase in nitric oxide synthase and thus nitric oxide. Nitric oxide then stimulates
angiogenesis of new blood vessels needed by cancer cells to thrive [58]. Esposito et al. (2016) found that
PXR activation could inhibit this process via its inhibition of the NF-κB pathway leading to decreased
levels of NO. Specifically, they found that when Caco2-human colon cancer cells were treated with a
non-absorbable antibiotic and PXR agonist rifaximin, there was a decrease in VEGF, NO, VEGFR-2,
MMP-2, and MMP-9 along with inhibition of HIF-1A, P-70S6K, and NF-κB. These effects were not
observed in cells co-treated with the PXR antagonist ketoconazole [58]. These results indicate a possible
inverse relationship between PXR activation and angiogenesis.
2.4. PXR and the Inflammatory Immune Response
Historically immune responses, such as inflammation, were thought to help eradicate tumors but
evidence is growing that antitumoral responses put pressure on the tumor to evade immune destruction.
The intersections between inflammation and cancer pathogenesis has shown the functionally important
tumor-promoting effects that immune cells in the innate system have on cancer progression [59]. It has
long been established that chronic inflammation can be a predisposition to cancer in a variety of
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settings. One example being the increased risk of colon cancer in patients with chronic inflammatory
bowel disease (IBD). This is thought to be mediated by proinflammatory factors which can induce
neoplastic mutations, resistance to apoptosis, and even stimulate angiogenesis [60]. Other studies
discuss an inflammatory component present in the microenvironment of tumors that contributes to
proliferation and survival of malignant cells, angiogenesis, metastasis, subversion of adaptive immunity,
and reduced response to hormones and chemotherapeutic agents known as cancer-related inflammation
(CRI) [61]. Transcription factors such as NF-κB and signal transducer activator of transcription-3 (Stat3)
and primary inflammatory cytokines, IL-1B, IL-6, and TNF-α are the primary players involved in CRI.
Inflammatory cytokines are known to affect PRX regulation either directly or indirectly by modifying
transcription factor expression and function such as in STAT3 and NF-κB in the liver, both transcription
factors of PXR [27,62,63]. There is substantial evidence that inflammation, with or without infection,
decreases the expression of enzymes involved in xenobiotic metabolism such as cytochrome P450
enzymes, however, the underlying mechanism behind this is not clear. For this reason, PXR is thought
to likely play a role in the progression of chronic inflammatory pathways. [64]. Lipopolysaccharide
(LPS) treatment, a bacterial endotoxin administered to cells or rodents to induce inflammatory changes,
has shown to downregulate the mRNA or protein levels, of both PXR and CYP [27]. Inflammatory
cytokines: IL-1B, IL-6, and TNFα, when upregulated following LPS treatment, lead to repression of PXR
and PXR-mediated CYP induction during inflammation [27]. Elevated levels of cytokine expression
following PXR deletion in mice suggests PXR plays a repressive role in regulating key inflammatory
mediators [65]. This data suggests there is negative regulation by LPS or LPS-induced cytokines
providing a molecular mechanism for inflammation impaired drug metabolism. Protein kinases such
as PKA and PKC, who become upregulated during inflammation, also affect PXR and ultimately CYP
regulation through transcriptional suppression.
Cancer-induced inflammation is present in at least 60% of patients with advanced cancer and should
be considered as a source of variability in the clearance of anticancer drugs [62]. Specifically the role
of CYP3A4, which is responsible for metabolizing many anticancer drugs, has been shown to have
significantly reduced activity when increased levels of inflammatory mediators are present such as IL-6
and C-reactive protein (CRP) [63,66]. The association of reduced CYP3A4 expression in the presence of
cancer is associated with the inflammatory response and the release of cytokines such as IL-6 from the
cancer into the blood. The increased circulating CRP and IL-6 along with reduced CYP3A4 activity
observed in a subset of cancer patients indicates the role of IL-6 as being a potential mediator in the
process [63]. Chronic inflammation has also been implicated in anorexia-cachexia, a condition about
half of all cancer patients suffer from [67]. It is characterized by lack of response to treatment, substantial
weight loss, and poor prognosis. Though not as common in hematological malignancies and breast
cancer, patients with anorexia-cachexia have been shown to have raised serum concentrations of IL-6
and CRP, again associating these inflammatory markers with survival in malignant disorders including
myeloma, melanoma, ovarian cancer, renal-cell carcinoma, and gastrointestinal cancers [66,67].
Recent studies have found a link between PXR and the proinflammatory mediator NF-κB. These
studies actually demonstrated an inverse relationship with activated PXR inhibiting NF-κB signaling.
It was also found that NF-κB target gene expression was upregulated in PXR knockout mice leading
to a proinflammatory state [64]. NF-κB was shown to downregulate both PXR and PXR-mediated
CYP expressions through protein–protein interactions of the PXR pathway [27,68]. Gu et al. (2006)
reported NF-κB activation by LPS or TNF-α suppressed PXR by interacting with the PXR-RXR
heterodimer and the suppressive effects could be reversed by the NF-κB specific suppressor SRIκBa [68].
Additionally, inhibition of NF-κB potentiating PXRs activity was also shown by Zhou et al. (2006) [64].
Both are examples of the PXR-NF-κb axis providing a molecular explanation for CYP expression to
be suppressed by inflammatory stimuli in hepatic and interstitial tissue. Less is known about STAT3
and PXR activity during inflammation though it has been shown IL-6 activates STAT3 which inhibits
the transcriptional activity of other nuclear receptors (NR) such as NNF4a and HNF4a-mediated CYP
induction [27,62,63]. The anti-inflammatory role of PXR is further supported by evidence that PXR is
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downregulated in patients with IBD and several polymorphisms that lead to decreased PXR activity
have been found; both have been linked to the presence of IBD in patients [69,70].
2.5. Role of PXR Polymorphisims
Genetic polymorphisims within the sequence of PXR, including several SNPs within the 30 UTR,
have been suggested to correlate with an increased predisposition to breast cancer by influencing its
expression and/or function [48,71]. Additionally, alterations in expression of target genes including
ABCB1 and CYP3A4 in breast cancer patients, which subsequently results in altered clearance of
xenobiotics and drug substrates, have been linked with PXR polymorphisms [72,73].
A number of SNPs within genes involved in the endobiotic metabolism of estrogen have been
suggested to alter breast cancer susceptibility, through modification of circulating estrogen levels.
A recent meta-analysis was performed on 10 studied SNPs in PXR and the susceptibility to overall
cancer [71]. Two of the 10 (rs3814058 C/T and rs3814057 A/C) were demonstrated to be associated
with an elevated risk of cancer. For the SNP rs3814058 C/T, heterozygote and homozygous variants
(dominant, recessive, and allelic models) were all correlated with an elevated risk of breast, lung,
and colorectal cancer in Asian populations. Additionally, for the SNP, rs3814057 A/C, the heterozygote
genotype and all dominant models were found to be correlated with an increased breast and colorectal
cancer risk in the entire patient population reviewed as part of the meta-analysis (patient home countries
of Germany, China, Malaysia, India, and Mexico). However, meta-analysis data specific to rs3814057
revealed three case-control studies, but none reported an associated cancer risk with rs3814057 [74].
Indeed, the MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy
Related Breast Cancer Risk reported a decreased risk of breast cancer associated with SNPs rs6785049
and rs1054191, in carriers who used combined estrogen–progesterone, post-menopausal hormone
therapy [75]. Seven specific PXR SNPs were analyzed in this patient population.
Revathidevi et al. (2016) screened the 30 UTR of PXR in 96 breast cancer patients to identify
polymorphisms that impact PXR expression levels [48]. They found three SNPs (rs3732360, rs1054190,
and rs1054190) which were shown to alter miRNA mediated regulation of PXR. In silico analysis
of these three SNPs revealed dramatic alterations to miRNA regulation; 9 new binding sites were
identified and 11 sites were eliminated in the 30 UTR of PXR. The efficiency of selected binding sites
was impacted as well: three miRNA sites resulted in increased binding efficiency while two sites
were diminished. Furthermore, altered miRNA-binding sites were evaluated for their involvement in
tumor progression and toxicity, and were associated with breast cancer pathogenesis, cardiotoxicity,
and treatment response [48].
3. Conclusions
PXR is expressed and is biologically functional in breast tissue, and a preponderance of evidence
suggests that it likely plays a key role in acquired chemoresistance. PXR effects on tissue growth,
metastasis, and apoptosis are very likely a tissue-specific phenomenon, whereby in one tissue it
may act as a growth proliferator (e.g., colon) but in others (e.g., breast) it could potentially have
an opposite or variable overall effect. There is good precedence for this notion as in enterocytes,
PXR activation regulates the drug-inducible expression of the MDR1 gene, whereas in liver it does
not [25,26,76]. This phenomenon is almost certainly due to tissue-specific and differential repertoire of
nuclear receptor coregulatory proteins available in the given cell type. Similar paradigms exist for
several other nuclear receptors. For example, the androgen receptor in breast cancer behaves differently
than in the prostate [77,78].
PXR has been shown to be moderately expressed in both ER+ and ER- breast tumors [79],
while others report PXR expression is inversely correlated with the expression of ER, suggesting that
PXR-mediated pathways might be more active in breast tumors which are less likely to respond to
endocrine therapies [37]. A more recent study suggests there is concomitant expression of PXR and ER,
with higher PXR expression leading to increased survival rate in ER+ tumors [57]. The range of effects
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of PXR based solely on ER status strongly suggest that further exploration into PXR and its role within
the defined molecular subtypes of breast cancers is warranted. The role of PXR and other nuclear
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